



**Notice Regarding the Acceptance of a Proposal for the AMED Public Solicitation
"Basic Technology Development Project for the Industrialization of Regenerative
Medicine and Gene Therapy"(Project Title: Development of Manufacturing Process for
Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for
Advanced/Recurrent Cervical Cancer)**

July 24, 2026

We hereby announce that our proposal for the "Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer" (hereinafter referred to as the "Project") has been adopted for the public solicitation program "FY2026 Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy" by the Japan Agency for Medical Research and Development (AMED).

AMED Link: https://www.amed.go.jp/koubo/03003/01/C_00003.html

Item	Details
Research and Development Project Title:	"Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer"
Planned Research Period:	Up to 3 years (FY2026 to FY2028)
Scale of Subsidized Expenses:	JPY 92,300 thousand (maximum) (excluding indirect costs)

Note: The final grant amount and the timing of its recognition will be determined upon receiving the notice of grant decision from AMED.

Overview of Research and Development:

Tumor-Infiltrating Lymphocyte (TIL) infusion therapy is a personalized immunotherapy in which immune cells present in a patient's own tumor tissue are cultured in large quantities ex vivo and then infused back into the patient's body to attack the cancer. In Japan, the safety and tolerability of TIL manufacturing and administration have already been confirmed under Advanced Medical Care B (Senshin Iryo B) (a Phase II clinical trial of short-term cultured anti-tumor lymphocyte infusion therapy using non-myeloablative conditioning and low-dose IL-2 for advanced cervical cancer).

Through joint research with Keio University, the International University of Health and Welfare, and other institutions, our Company has received the transfer of advanced TIL culture technology pioneered in Japan, and has been undertaking the contract manufacturing of TIL products used in the aforementioned Advanced Medical Care. Through these activities, our Company has accumulated a solid manufacturing track record and extensive cell processing know-how at the clinical research level.

In this Project, we will conduct research and development to construct a commercial manufacturing process compliant with pharmaceutical regulations and to establish a quality assurance system, aiming for the early initiation of company-sponsored clinical trials.

As the formal determination of the exact grant amount is expected to take place in the next fiscal year or

later, we will promptly announce the details once they are confirmed. Please note that this matter will have no impact on the Company's consolidated financial results for the fiscal year ending March 31, 2027.

Tumor-Infiltrating Lymphocyte (TIL) Infusion Therapy

This is a type of adoptive immunotherapy in which immune cells called tumor-infiltrating lymphocytes (TILs), found within the patient's own cancer tissue, are harvested, cultured ex vivo in large quantities, and infused back into the patient. It is primarily administered for advanced malignant melanoma, where high therapeutic efficacy has been reported. It is known that patients who achieve a complete response (complete disappearance of lesions) generally do not relapse, with a few exceptions. There are also reports of complete responses and long-term recurrence-free survival in patients with recurrent cervical cancer. In the United States, company-sponsored clinical trials of TIL therapy for cervical cancer have also commenced.